Aptose Biosciences Inc.

OTCPK:APTO.F Stok Raporu

Piyasa değeri: US$4.0m

Aptose Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Aptose Biosciences CEO'su William Rice, Oct2013 tarihinde atandı, in görev süresi 12.67 yıldır. in toplam yıllık tazminatı $ 1.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.8% maaş ve 37.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler $ 7.02K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 12.7 yıldır.

Anahtar bilgiler

William Rice

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi62.81%
CEO görev süresi12.7yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi6.4yrs
Yönetim Kurulu ortalama görev süresi12.7yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Aug 01

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q2 earnings results on Monday, August 1st, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 6 upward revisions and 0 downward.
Seeking Alpha • Jul 19

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023. There is a sizable market opportunity for drugs to address patients with hematological cancers who've progressed on other therapies, but the odds and timelines are long. I believe fair value for Aptose is around $4 today, but upside is tied to future positive clinical developments and there's not much room for stumbles or setbacks. It wouldn't be fair to say that there's been no clinical progress at Aptose Biosciences (APTO) since my last update, but there certainly hasn't been enough to really sway investor sentiment, particularly in light of a more risk-averse biotech market. Aptose has two credible hematological oncology products in the pipeline, but there is a still lot of de-risking needed for both programs. I do believe that the market is still heavily discounting the odds of clinical success here, but given the history of oncology drug development, and Aptose's own shaky clinical progress, that's not exactly unfair. I can still see a path toward a substantially higher fair value, but the reality is that investors are likely going to need to wait a year or more for sentiment-moving data. '239 Is Worth Further Exploration From five complete responses and one partial response back at the December 2021 ASH update, Aptose has seen two more complete responses in its HM43239 (or '239) program in relapsed or refractory AML, bringing the total to seven complete responses and one partial response among a 80mg, 120mg, and 160mg dosing group that has treated at least 41 patients as off the last cut-off (early June, ahead of the EHA meeting). Thus far the drug has shown encouraging safety/tolerability, with only one dose-limiting toxicity reported so far (muscle weakness in a patient getting a 200mg dose). While the response rates aren't eye-popping at this point, it's worth remembering that these are not the healthiest patients, as they've already seen drug progression after prior treatments. Based on the early clinical results, management is moving forward with further dose exploration at 80mg, 120mg, and 160mg (the 80mg segment has been completed, with the 120mg and 160mg cohorts about half-complete as of early June) and then two expansion studies. One expansion study will use 120mg (with 80mg and 160mg as bracketing dosages) of '293 as a single-agent therapy in FLT-3 mutated and unmutated AML, while the other will be a combination study with venetoclax (Venclexta, marketed by AbbVie (ABBV) and Roche (RHHBY)). The single-agent study should start later this year, with the combo study slated for the first half of 2023. Should the results of these studies merit it, registrational studies would then start - presumably in 2024 for the single-agent study. It's worth remembering that '293 is targeting the challenging r/r AML market. While there are solid treatment options available as front-line therapies, some patients cannot tolerate them, some do not respond, and others ultimately see their disease mutate around the treatment and become non-responsive/relapsing. Keep this in mind when comparing response rates to other drugs in the space (make sure it's an "apples to apples" comparison). Another Chance For Luxeptinib Aptose's prior lead drug, luxeptinib, still factors significantly into the company's clinical plans today. While the drug showed exciting pre-clinical attributes, clinical results today have not matched that potential. It would seem that the pharmacokinetics of the drug are at least partly to blame, and the company is hoping that a reformulated version of the drug (known as "G3") can lead to patients getting consistent therapeutic doses that produce clinical results. Clinical trial work is underway now, with patients getting G3 at 50mg, 100mg, and 200mg doses and the 50mg dose of G3 demonstrating 200x the exposure level of a 150mg dose of G1. Assuming that the pharmacokinetics and pharmacodynamics (PK and PD) studies merit further development, Aptose should be able to start dose escalation studies of the new formulation in the first half of 2023 in patients with r/r B-cell or r/r AML disease.
Seeking Alpha • Feb 02

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech. A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, but it's a "show me" story. Recently-acquired '239 looks like an interesting asset for AML, with promising Phase 1 response rates, but it's still early in the development cycle. Between '239 and luxeptinib there is still potential in Aptose's pipeline, but it will take real evidence of clinical efficacy to rebuild sentiment.

CEO Tazminat Analizi

William Rice'un ücretlendirmesi Aptose Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$28m

Dec 31 2025US$1mUS$677k

-US$25m

Sep 30 2025n/an/a

-US$19m

Jun 30 2025n/an/a

-US$21m

Mar 31 2025n/an/a

-US$21m

Dec 31 2024US$1mUS$647k

-US$25m

Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$47m

Dec 31 2023US$925kUS$623k

-US$51m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$44m

Dec 31 2022US$2mUS$599k

-US$42m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

-US$58m

Mar 31 2022n/an/a

-US$61m

Dec 31 2021US$2mUS$582k

-US$65m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$12mUS$582k

-US$55m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$562k

-US$26m

Tazminat ve Piyasa: William 'nin toplam tazminatı ($USD 1.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.92K ).

Tazminat ve Kazançlar: William 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

William Rice (67 yo)

12.7yrs
Görev süresi
US$1,077,641
Tazminat

Dr. William G. Rice, Ph D., had served as an Independent Director of Oncolytics Biotech Inc. since June 08, 2015 until June 30, 2021. He has been the Chief Executive Officer and President of Aptose Bioscie...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
William Rice
Chairman12.7yrsUS$1.08m0.18%
$ 7.0k
Fletcher Payne
Senior VP4yrsUS$710.58k0.0096%
$ 382.8
Rafael Bejar
Senior VP & Chief Medical Officer6.4yrsUS$754.62k0.0096%
$ 382.8
6.4yrs
Ortalama Görev Süresi
63yo
Ortalama Yaş

Deneyimli Yönetim: APTO.F 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
William Rice
Chairman12.7yrsUS$1.08m0.18%
$ 7.0k
Mark Vincent
Independent Director18.8yrsUS$95.00k0.00055%
$ 22.0
Bernd Seizinger
Independent Director3.8yrsUS$103.50k0.022%
$ 887.8
Denis Burger
Lead Independent Director18.8yrsUS$128.50k0.0019%
$ 75.3
Stephen Howell
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Daniel Von Hoff
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Erich Platzer
Independent Director11.5yrsUS$90.00k0.044%
$ 1.8k
Warren Whitehead
Independent Director15.2yrsUS$80.00k0.0013%
$ 51.7
Brian Druker
Chairman of Scientific Advisory Board12.7yrsVeri yokVeri yok
Michael Andreeff
Member of Scientific Advisory Board11.3yrsVeri yokVeri yok
12.7yrs
Ortalama Görev Süresi
74yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: APTO.F 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 12.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/12 17:25
Gün Sonu Hisse Fiyatı2026/06/10 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Aptose Biosciences Inc. 9 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Matthew VeneziaAlliance Global Partners
Dylan DupuisB. Riley Securities, Inc.
John NewmanCanaccord Genuity